Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -34.73
- Piotroski Score 4.00
- Grade Buy
- Symbol (EBET)
- Company EBET, Inc.
- Price $0.00
- Changes Percentage (150%)
- Change -$0
- Day Low $0.00
- Day High $0.00
- Year High $0.40
EBET, Inc. develops products and operates platforms to provide a real money online gambling experience focused on esports and competitive gaming. The company operates a portfolio of proprietary online casino and sportsbook brands consisting of Karamba, Hopa, Griffon Casino, BetTarget, Dansk777, and GenerationVIP. It also provides iGaming, which include online casino and table games, such as blackjack, virtual sport computer simulated games, and slot machines, as well as traditional sports betting. The company was formerly known as Esports Technologies, Inc. and changed its name to EBET, Inc. in May 2022. EBET, Inc. was incorporated in 2020 and is based in Las Vegas, Nevada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/27/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$9.96
- Trailing P/E Ratio -0.02
- Forward P/E Ratio -0.02
- P/E Growth -0.02
- Net Income $-84,243,877
Income Statement
Quarterly
Annual
Latest News of EBET
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
DRI Healthcare Trust Acquires Royalty in Pre-Approval Sebetralstat for Up to $179 Mln
DRI Healthcare Trust bought a royalty interest in Sebetralstat, a drug for hereditary angioedema, for $179 million. The drug is in the approval process with the FDA and EMA, potentially becoming the f...
By MarketWatch | 2 weeks ago -
Is Goldman Sachs ActiveBeta World Low Vol Plus Equity ETF (GLOV) a Strong ETF Right Now?
The Goldman Sachs ActiveBeta World Low Vol Plus Equity ETF (GLOV) is a smart beta ETF offering exposure to Broad Developed World ETFs. It aims to outperform by tracking non-cap weighted strategies, di...
By Yahoo! Finance | 3 months ago
